ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour


Geneva, Switzerland, 26 February 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth, announced today the results of a Phase 1 drug interaction study for its lead compound, OBE001. OBE001 is a novel orally active oxytocin receptor antagonist, which ObsEva is developing for the treatment of preterm labour.